---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-011895"
form_type: "8-K"
ticker: "PBSV"
cik: "0001304161"
company_name: "Pharma-Bio Serv, Inc."
filed_at: "2023-09-14T23:59:59+00:00"
generated_at: "2026-06-10T17:22:33.985077+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pharma-Bio Serv Q3 net income up $0.2M to $0.5M; revenue down $0.2M to $4.6M

## Summary
- Net income for Q3 FY2023 (three months ended July 31) was approx $0.5M, up from $0.3M YoY; nine-month net income $1.4M vs $0.9M.
- Q3 revenue $4.6M, down from $4.8M YoY; nine-month revenue $13.4M vs $14.8M.
- Gross profit margin improved 6.4 percentage points in Q3 and 5.3 percentage points YTD.
- CEO Sanchez highlighted successful strategy, new market expansion, and leveraging FDA scrutiny for profitability.

## SEC filing metadata
- accession: 0001654954-23-011895
- form_type: 8-K
- ticker: PBSV
- cik: 0001304161
- company_name: Pharma-Bio Serv, Inc.
- filed_at: 2023-09-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1304161/000165495423011895/0001654954-23-011895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1304161/000165495423011895/pbsv_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-011895
- JSON: https://secwatch.observer/filing/0001654954-23-011895.json
- Plain text: https://secwatch.observer/filing/0001654954-23-011895.txt

## Key facts
- Earnings Releases
  Pharma-Bio Serv, Inc. reported financial results for the three and nine months ended July 31, 2023.
  - Period: the three and nine months ended July 31, 2023
  - Result: reported results
  source text: On September 14, 2023, Pharma-Bio Serv, Inc. (the “Company”) issued a press release announcing its results of operations for the three and nine months ended July 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1304161/000165495423011895/0001654954-23-011895-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.